Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Open Access
- 2 September 2021
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 59 (3), 2004538
- https://doi.org/10.1183/13993003.04538-2020
Abstract
The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib on ILD progression over the whole trial. Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had ILD progression within the 24 months before screening despite management deemed appropriate in clinical practice, were randomised to receive nintedanib or placebo. Subjects continued on blinded randomised treatment until all subjects had completed the trial. Over the whole trial, mean (sd) exposure to trial medication was 15.6 (7.2) and 16.8 (5.8) months in the nintedanib and placebo groups, respectively. In the nintedanib (n=332) and placebo (n=331) groups, respectively, the proportions of subjects who had ILD progression (absolute decline in FVC ≥10% predicted) or died were 40.4% and 54.7% in the overall population (HR 0.66 [95% CI: 0.53, 0.83]; p=0.0003), and 43.7% and 55.8% among subjects with a usual interstitial pneumonia (UIP)-like fibrotic pattern on high-resolution computed tomography (HRCT) (HR 0.69 [0.53, 0.91]; p=0.009). In the nintedanib and placebo groups, respectively, the proportions who had an acute exacerbation of ILD or died were 13.9% and 19.6% in the overall population (HR 0.67 [95% CI: 0.46, 0.98]; p=0.04), and 15.0% and 22.8% among subjects with a UIP-like fibrotic pattern on HRCT (HR 0.62 [0.39, 0.97]; p=0.03). Based on data from the whole INBUILD trial, nintedanib reduced the risk of events indicating ILD progression.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 21 references indexed in Scilit:
- Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseasesEuropean Respiratory Review, 2018
- What's in a name? That which we call IPF, by any other name would act the sameEuropean Respiratory Journal, 2018
- Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitisThorax, 2017
- Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic SclerosisArthritis & Rheumatology, 2017
- Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group ReportAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trialsRespiratory Medicine, 2016
- Predictors of mortality in rheumatoid arthritis-associated interstitial lung diseaseEuropean Respiratory Journal, 2015
- Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosisRespiratory Research, 2015
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2014
- Forced Vital Capacity in Patients with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011